Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $124 price target.
Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $124 price target.